Holen Sie sich die Stockscreener-App
263.60
6.93%
14.69
Schlusskurs vom Vortag:
$248.91
Offen:
$254.51
24-Stunden-Volumen:
61,673
Relative Volume:
0.22
Marktkapitalisierung:
$7.65B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
88.16
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
+7.80%
1M Leistung:
+13.43%
6M Leistung:
+78.75%
1J Leistung:
+69.88%
1-Tages-Spanne:
$252.92
$267.48
1-Wochen-Bereich:
$235.60
$267.48
52-Wochen-Spanne:
$122.80
$267.48
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Vergleichen Sie KRYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
263.94 | 7.22B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India
KRYS: HC Wainwright & Co. Raises Price Target to $310 | KRYS Sto - GuruFocus
Krystal Biotech stock price target raised to $288 from $272 at BofA - Investing.com UK
Jefferies raises Krystal Biotech stock price target to $310 on CF data By Investing.com - Investing.com South Africa
Jefferies raises Krystal Biotech stock price target to $310 on CF data - Investing.com India
Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data - Sahm
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path - Yahoo Finance
Can Krystal Biotech Inc. stock continue upward trend2025 Support & Resistance & Risk Managed Investment Signals - ulpravda.ru
Will Krystal Biotech Inc. stock benefit from upcoming earnings reportsJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - ulpravda.ru
Will Krystal Biotech Inc. stock benefit from AI adoptionLong Setup & High Accuracy Investment Signals - ulpravda.ru
Krystal Biotech advances KB407 with positive CF trial data - TipRanks
What Wall Street predicts for Krystal Biotech Inc. stock priceJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - ulpravda.ru
Krystal Biotech (KRYS) Reports Promising Interim Results from CORAL-1 Study - GuruFocus
Krystal Biotech, Inc. Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study - TradingView — Track All Markets
Will Krystal Biotech Inc. stock reach all time highs in 2025Portfolio Value Summary & Real-Time Market Trend Scan - ulpravda.ru
Krystal Biotech confirms CFTR delivery in CF patients with KB407 By Investing.com - Investing.com India
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis - Stock Titan
Trend Recap: Will Krystal Biotech Inc. stock reach all time highs in 2025 - ulpravda.ru
How Krystal Biotech Inc. (4KB) stock responds to bond marketWeekly Gains Summary & Fast Moving Market Watchlists - ulpravda.ru
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? - Finviz
Krystal Biotech to share interim results from cystic fibrosis trial By Investing.com - Investing.com Nigeria
Krystal Biotech Announces Investor Conference Call for Interim Clinical Update on KB407 in Cystic Fibrosis Study - Quiver Quantitative
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis - The Manila Times
Citigroup Upgrades Krystal Biotech (KRYS) - Nasdaq
Krystal Biotech (KRYS) Receives Upgraded Rating and Price Target Boost from Citigroup | KRYS Stock News - GuruFocus
Krystal Biotech Shares Rise After Citigroup Upgrade - MarketScreener
Citigroup Upgrades Krystal Biotech to Buy From Neutral, Adjusts Price Target to $309 From $198 - marketscreener.com
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 5,800 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shareholders Have Earned a 30% CAGR Over the Last Five Years - 富途牛牛
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Krystal Biotech, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - Quiver Quantitative
Will Krystal Biotech Inc 4KB stock outperform global peersPortfolio Update Report & Daily Entry Point Alerts - moha.gov.vn
Krystal Biotech Inc Stock Analysis and ForecastVolume Analysis Techniques & Hedge Fund-Style Analysis Now Free - earlytimes.in
Growth Value: Can Krystal Biotech Inc stock deliver surprise earnings beatM&A Rumor & Fast Gaining Stock Reports - moha.gov.vn
Discipline and Rules-Based Execution in KRYS Response - Stock Traders Daily
Rally Mode: Can Krystal Biotech Inc stock continue upward trendJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Exploring High Growth Tech Stocks In The US For December 2025 - simplywall.st
Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week HighWhat's Next? - MarketBeat
Bearish Setup: Can Krystal Biotech Inc stock continue upward trend2025 Historical Comparison & Safe Entry Momentum Tips - moha.gov.vn
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating a $7.31 Billion Market Cap with Promising Genetic Medicines - DirectorsTalk Interviews
Krystal Biotech Earnings Notes - Trefis
Krystal Biotech announces resignation of longtime board member - TipRanks
Krystal Biotech Announces Board Resignation - TradingView — Track All Markets
Krystal Biotech, Inc. Announces Resignation of Kirti Ganorkar as Director, Effective December 31, 2025 - marketscreener.com
Krystal Biotech, Inc. $KRYS Shares Purchased by Voya Investment Management LLC - MarketBeat
Krystal Biotech stock hits all-time high at 248.82 USD By Investing.com - Investing.com Nigeria
Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week HighShould You Buy? - MarketBeat
Krystal Biotech stock hits all-time high at 248.82 USD - Investing.com
Trading the Move, Not the Narrative: (KRYS) Edition - Stock Traders Daily
Why Krystal Biotech Inc. stock remains on buy listsWeekly Risk Report & Real-Time Market Sentiment Reports - Улправда
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):